Cite
Weinberg DS, Foster NR, Della'Zanna G, et al. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer Biol Ther. 2021;22(10):544-553doi: 10.1080/15384047.2021.1967036.
Weinberg, D. S., Foster, N. R., Della'Zanna, G., McMurray, R. P., Kraft, W. K., Pallotto, A., Kastenberg, D. M., Katz, L. C., Henry, C. H., Moleski, S. M., Limburg, P. J., & Waldman, S. A. (2021). Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer biology & therapy, 22(10), 544-553. https://doi.org/10.1080/15384047.2021.1967036
Weinberg, David S, et al. "Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers." Cancer biology & therapy vol. 22,10 (2021): 544-553. doi: https://doi.org/10.1080/15384047.2021.1967036
Weinberg DS, Foster NR, Della'Zanna G, McMurray RP, Kraft WK, Pallotto A, Kastenberg DM, Katz LC, Henry CH, Moleski SM, Limburg PJ, Waldman SA. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer Biol Ther. 2021 Dec 02;22(10):544-553. doi: 10.1080/15384047.2021.1967036. Epub 2021 Oct 10. PMID: 34632925.
Copy
Download .nbib